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than angiotensin receptor blockade
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To explore the potential therapeutic effects of
angiotensin(1–7) (Ang(1–7)), an endogenous ligand of the
Mas receptor, on streptozotocin-induced diabetic
nephropathy, male Wistar rats were randomly divided into
two groups: a control group and a diabetic model group.
After 12 weeks, the diabetic rats were divided into subgroups
for 4-week treatments consisting of no-treatment group,
small-, moderate-, and large-dose Ang(1–7) groups, a valsartan
group, a large-dose Ang(1–7) plus valsartan group, and an
A779 (antagonist of the Mas receptor) group, each with 15
rats. Ang(1–7) improved renal function, attenuated glomeruli
sclerosis, oxidative stress, and cell proliferation, decreased
the expression of collagen IV, TGF-b1, VEGF, NOX4, p47phox,
PKCa, and PKCb1, and the phosphorylation of Smad3. In the rat
mesangial HBZY-1 cell line, Ang(1–7) decreased high-glucose-
induced oxidative stress, the proliferation and expression of
NOX4, p47phox, and TGF-b1, the phosphorylation of Smad3,
collagen IV, and VEGF, and the membrane translocation of
PKCa and PKCb1. A779 blocked the effects of Ang(1–7) both
in vivo and in vitro. The effects of large-dose Ang(1–7) alone
and in combination with valsartan were superior to valsartan
alone, but the combination had no significant synergistic
effect compared with Ang(1–7) alone. Thus, Ang(1–7)
ameliorated streptozotocin-induced diabetic renal injury.
Large-dose treatment was superior to valsartan in reducing
oxidative stress and inhibiting TGFb1/Smad3- and
VEGF-mediated pathways.
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Diabetic nephropathy (DN) has become the most common
cause of end-stage renal disease, and it represents an increasing
global public health problem.1,2 A wealth of evidence indicates
that the renin–angiotensin system has a key role in the patho-
genesis of DN, and a galaxy of clinical trials have proven that
angiotensin-converting enzyme inhibitors and type 1 angio-
tensin receptor antagonists are effective in attenuating the
development of DN.3,4 These protective effects were originally
thought to result from blocking angiotensin II–dependent
pathways. However, the recent discovery of a homolog of
angiotensin-converting enzyme, ACE2, revealed a new path-
way for angiotensin peptide metabolism.5,6 ACE2 generates
angiotensin(1–7) (Ang(1–7)) from angiotensin II5 and has a
protective role against DN.7,8 However, the effect of Ang(1–7),
the primary product of ACE2, on DN remains poorly
understood.
Ang(1–7) as a heptapeptide is mainly derived from the
degradation of angiotensin II by ACE2 in the kidney.9 The
concentration of Ang(1–7) was six times higher in the kidney
than in plasma,9 suggesting an intrarenal production of
Ang(1–7). Consistent with its site of synthesis, Ang(1–7) exerts
important effects on renal homeostasis. In proximal tubular
cells, Ang(1–7) activates tyrosine phosphatase and inhibits
high-glucose-stimulated p38 MAPK, thereby suppressing
high-glucose-induced protein synthesis.10 Ang(1–7) attenuates
renal vascular dysfunction by alleviating nicotinamide adenine
dinucleotide phosphate oxidase (NOX)–mediated oxidative
stress in diabetic and hypertensive rats.11 However, a recent
study using a moderate dose of Ang(1–7) to treat DN reported
no benefit of Ang(1–7) treatment in reducing the levels of
serum creatinine and creatinine clearance, or the ratio of kidney
weight/body weight (%).12 In another study, an injection of
a moderate dose of Ang(1–7) paradoxically accelerated strep-
tozotocin (STZ)-induced diabetic renal injury.13 So far, several
important issues remain unsolved. First, whether Ang(1–7)
treatment is beneficial or harmful to DN is controversial.
Second, the effect of different doses of Ang(1–7) on DN is to
be defined. Third, it is unclear whether combined treatment
with Ang(1–7) and an angiotensin receptor blocker is superior
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to either treatment alone for DN. Finally, the possible
mechanisms underlying the effect of Ang(1–7) on DN are
only poorly understood. To address these critical issues, we
hypothesize that Ang(1–7) may ameliorate STZ-induced
diabetic renal injury, and the effect of large-dose Ang(1–7)
treatment was superior to that of valsartan by reducing
oxidative stress induced by nicotinamide adenine dinucleo-
tide phosphate oxidase and protein kinase C (PKC), and by
inhibiting tumor growth factor-b1 (TGFb1)/Smad3 and
vascular endothelial growth factor (VEGF) signaling. A
number of in vivo and in vitro experiments were designed
and performed to validate this hypothesis in this study.
RESULTS
Serum and urine levels of Ang(1–7)
The serum and urinary levels of Ang(1–7) in seven diabetic
groups were significantly lower than in the control group
before Ang(1–7) treatment, but they were significantly
increased in the six treatment groups after treatment
(Figure 1a and b).
Blood pressure and glucose levels
At the end of the experiment, systolic blood pressure (SBP)
was significantly lower in all seven groups of diabetic rats
than in the control group of rats, but there was no significant
difference in SBP among seven groups of diabetic rats
(Figure 1c). The blood glucose levels in all seven diabetic
groups were markedly higher than in the control group, but
they did not differ among seven diabetic groups (Table 1).
Ang(1–7) dose-dependently ameliorated renal function
At the end of the experiment, kidneys in DM rats without
treatment were heavier than those in other groups, but the
difference was not statistically significant (Figure 1d). Body
weight and creatinine clearance were significantly lower in
seven groups of diabetic rats than those in the control group
of rats. However, these parameters were dose-dependently
increased in all treatment groups of diabetic rats except for
the large-dose Ang(1–7)þ A779 group, in which the body
weight and creatinine clearance were similar to those in the
no-treatment group (Table 1; Figure 1f). The ratio of kidney
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Figure 1 | Ang(1–7) levels, blood pressure, and renal function in eight groups of rats. (a) Serum levels of Ang(1–7) (n¼ 5 per group).
(b) Urinary levels of Ang(1–7) (n¼ 5 per group); *Po0.05 vs. control group at the same time point; #Po0.05 vs. the same group at the end
of week 12. (c) Systolic blood pressure. (d) Kidney weight. (e) 24-h urinary albumin. (f) Creatinine clearance. (g) Malondialdehyde content.
(h) Superoxide dismutase (SOD) activity. *Po0.05 vs. the control group; #Po0.05 vs. the no-treatment group; yPo0.05 vs. the valsartan group.
NT: no treatment; S-Ang(1–7): small-dose Ang(1–7); M-Ang(1–7): moderate-dose Ang(1–7); L-Ang(1–7): large-dose Ang(1–7); LþV: large-dose
Ang(1–7)þValsartan; LþA779: large-dose Ang(1–7)þ A779.
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weight to body weight, 24-h urinary volume, plasma creati-
nine level, and 24-h urinary albumin excretion were all
significantly higher in seven groups of diabetic rats than in
the control group of rats (all Po0.05, Table 1; Figure 1e).
These values were decreased dose-dependently in all treat-
ment groups of diabetic rats except for the large-dose
Ang(1–7)þ A779 group, in which these values returned to
the level of the no-treatment group (Table 1, Figure 1e).
Compared with the valsartan treatment group, the ratio of
kidney weight to body weight, 24-h urinary volume, plasma
creatinine level, and 24-h urinary albumin excretion were all
significantly decreased, whereas creatinine clearance was
significantly increased in the large-dose Ang(1–7) treatment
and large-dose Ang(1–7)þ valsartan treatment groups, but
these parameters did not differ between the two treatment
groups (Table 1; Figure 1e and f).
Ang(1–7) reduced mesangial matrix expansion
Extracellular matrix deposition was detected by periodic
acid–Schiff staining, and glomeruli sclerosis index (GSI) was
calculated. GSI was significantly higher in the seven diabetic
groups than in the control group (Po0.05, Figure 2).
Compared with the no-treatment group, GSI was signifi-
cantly decreased in the small-, moderate-, and large-dose
Ang(1–7) groups, the valsartan group, and the large-dose
Ang(1–7)þ valsartan group, and the effect of Ang(1–7) on
GSI was dose dependent and blocked by A779 treatment
(Figure 2). The effect on GSI was similar in the large-dose
Ang(1–7) and large-dose Ang(1–7)þ valsartan treatment
groups, but was greater in these two groups than in the
valsartan group (Po0.05, Figure 2).
Immunohistochemical staining revealed an increased
expression of collagen IV, TGF-b1, VEGF, and proliferating
cell nuclear antigen in the glomeruli of the seven diabetic
groups (all Po0.05, Figure 3), relative to the control group.
However, in comparison with the no-treatment group, the
expression levels of collagen IV, TGF-b1, VEGF, and pro-
liferating cell nuclear antigen were substantially decreased in
the small-, moderate-, and large-dose Ang(1–7) groups, which
was dose dependent and offset by A779 treatment, as well as
in the valsartan group and the large-dose Ang(1–7)þ valsartan
group (Figure 3). These beneficial effects in the large-dose
Ang(1–7) group were similar to those in the large-dose
Ang(1–7)þ valsartan group, but were superior to those in the
valsartan group (Figure 3). On the other hand, macrophage
infiltration in kidneys, a measure of inflammation, did not
differ significantly among the control and seven diabetic
groups of rats (P40.05, Figure 3a).
Ang(1–7) attenuated oxidative stress in DN rats and
mesangial cells
To evaluate the effects of Ang(1–7) on oxidative stress in DN,
we detected malondialdehyde (MDA) content and superoxide
dismutase (SOD) activity in glomeruli. Compared with
the control group, MDA content was significantly higher,
whereas total SOD activity was significantly lower, in the no-
treatment group (Po0.05, Figure 1g and h). In contrast, the
level of MDA was markedly lowered, whereas the activity
of SOD increased in the small-, moderate-, and large-dose
Ang(1–7) groups, large-dose Ang(1–7)þ valsartan group,
and valsartan group in comparison with the no-treatment
group, with the superior effects being observed in the large-
dose Ang(1–7) and large-dose Ang(1–7)þ valsartan groups
relative to the valsartan group (Figure 1g and h). Again, the
salutary effects obtained by large-dose Ang(1–7) treatment
were largely blocked by the combined A779 treatment
(Figure 1g and h).
The level of reactive oxygen species (ROS) in glomerular
mesangial HBZY-1 cells, as determined by dihydroethidium
and dichlorofluorescein staining, was significantly increased
after high glucose stimulation (Po0.05, Figure 4a–c).
The content of ROS was dose-dependently attenuated by
Ang(1–7) treatment, but this effect was virtually offset by
combined A779 treatment (P40.05, Figure 4a–c). Similar to
the in vivo effects, large-dose Ang(1–7) treatment alone or in
combination with valsartan reduced ROS content to a greater
extent than valsartan treatment alone (Po0.05, Figure 4a–c).
Ang(1–7) decreased NOX and PKC expression in DN rats and
mesangial cells
Increased NOX activity and activation of the PKC system in
renal tissues have a key role in the development of DN,14 and
Table 1 | Biochemical and pathological measurements in eight groups of rats
Groups (n¼ 15 per group) Blood glucose (mmol/l) Body weight (g) KW/BW (mg/g) 24-h UV (ml) Plasma creatinine level (lmol/l)
Control 3.91±0.90 533.20±14.31 6.41±1.20 33.00±3.00 24.00±2.58
NT 22.43±2.60a 246.25±6.70a 14.39±0.81a 156.33±10.69a 62.80±2.17a
S-Ang(1–7) 22.96±1.94a 256.25±4.35a,b,c 13.11±0.20a,b,c 108.00±5.29a,b,c 54.75±2.06a,b,c
M-Ang(1–7) 22.35±1.97a 276.75±5.38a,b 12.02±0.12a,b 78.67±3.51a,b 46.67±1.53a,b
L-Ang(1–7) 21.76±2.54a 310.00±7.12a,b,c 10.25±0.24a,b,c 56.33±5.03a,b,c 36.50±2.89a,b,c
Valsartan 22.44±2.55a 288.43±6.11a,b 11.12±0.22a,b 77.67±3.51a,b 45.75±2.87a,b
LþV 23.23±3.18a 309.25±10.24a,b,c 10.49±0.30a,b,c 56.00±5.29a,b,c 38.20±2.68a,b,c
LþA779 23.19±3.12a 247.00±6.48a,c 14.18±0.53a,c 152.00±8.00a,c 60.40±2.88a,c
Abbreviations: KW/BW, kidney weight/body weight; LþA779, large-dose Ang(1–7)þA779; L-Ang(1–7), large-dose Ang(1–7); LþV, large-dose Ang(1–7)þ valsartan;
M-Ang(1–7), moderate-dose Ang(1–7); NT, no treatment; S-Ang(1–7), small-dose Ang(1–7); UV, urinary volume.
aPo0.05 vs. the control group.
bPo0.05 vs. the no-treatment group.
cPo0.05 vs. the valsartan group.
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thus we detected the effect of Ang(1–7) on the protein expres-
sion of NOX subunits NOX4 and p47phox and PKC isoforms
PKCa and PKCb1 in glomeruli. The expression of these
factors in the no-treatment group was higher than that in the
control group, but it was remarkably lower in the small-,
moderate-, and large-dose Ang(1–7) groups, the large-dose
Ang(1–7)þ valsartan group, and the valsartan group
than that in the no-treatment group (all Po0.05, Figure 5).
The therapeutic effect of Ang(1–7) was dose dependent
and similar in the large-dose Ang(1–7) and large-dose
Ang(1–7)þ valsartan groups, but it was superior in these two
treatment groups to that in the valsartan group (Figure 5).
Again, the beneficial effects accomplished by large-dose
Ang(1–7) treatment were largely canceled by the combined
A779 treatment (Figure 5).
Ang(1–7) dose-dependently attenuated the upregulated
expression of NOX4 and p47phox after high glucose stimula-
tion in HBZY-1 cells, and the effect of large-dose Ang(1–7)
was similar to the combined treatment with large-dose
Ang(1–7) and valsartan but was more prominent than treatment
with valsartan alone (Figure 6a and b). In contrast, A779
treatment prevented the effect of Ang (1–7) on the expres-
sion of these factors (Figure 6a and b). As membrane
translocation of PKCs is an important indicator of PKC
activation,15 we measured the protein expression levels of
PKCa and PKCb1 in membrane and cytosolic fractions of
HBZY-1 cells. We found that high-concentration glucose
stimulation significantly increased the protein levels of PKCa
and PKCb1 in the membrane fraction, which was attenuated
by treatment with the small-, moderate-, and large-dose
Ang(1–7), valsartan, or large-dose Ang(1–7)þ valsartan,
and the effect of large-dose Ang(1–7) treatment and
combined treatment was similar but was significantly
greater than that of valsartan treatment alone (Figure 6c
and e). In contrast, A779 treatment prevented the effect of
Ang (1–7) on the expression of both factors in the membrane
fraction (Figure 6c and e). However, the expression levels of
PKCa and PKCb1 in the cytosolic fraction were not
significantly different among eight groups of cells (P40.05,
Figure 6d and f).
Ang(1–7) inhibited the TGF-b1/Smad3 and VEGF signal
pathway and the expression of collagen IV in DN rats and
mesangial cells
The TGF-b1/Smad3 signal pathway regulates the hypertro-
phic and prosclerotic changes in diabetic renal injury.16
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Figure 2 | Effect of Ang(1–7) and valsartan treatment on mesangial matrix expansion in eight groups of rats. (a) Representative light
micrographs of periodic acid–Schiff (PAS) staining. (b) Quantification of glomeruli sclerosis index based on the amount of PAS-positive staining.
Bar¼ 50mm. *Po0.05 vs. the control group; #Po0.05 vs. the no-treatment group; yPo0.05 vs. the valsartan group. NT: no treatment;
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LþA779: large-dose Ang(1–7)þ A779.
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Large-dose Ang(1–7) treatment alone and in combination
with valsartan significantly decreased the expression of TGF-
b1 and the phosphorylation levels of Smad3 (p-Smad3) in
the glomeruli of DN rats and HBZY-1 cells stimulated by
high glucose, and the effect of large-dose Ang(1–7) and
large-dose Ang(1–7)þ valsartan treatments was superior to
that of valsartan treatment alone (all Po0.05, Figure 7a–d).
We also examined the effect of Ang(1–7) treatment on the
expression of collagen IV and VEGF in DN rats (Figure 3a, b
and d) and mesangial cells (Figure 7e–h), which showed
similar changes as TGF-b1. Once again, A779 treatment
blocked the salutary effect of Ang(1–7) in vivo and in vitro
(Figure 3 and 6).
Proliferation of glomerular mesangial cells
Mesangial cell proliferation has an essential role in the
progression of DN.17 We found that high glucose signifi-
cantly increased the proliferation of HBZY-1 cells, as detected
by 5-ethynyl-20-deoxyuridine incorporation, whereas treatment
with small-, moderate-, and large-dose Ang(1–7), valsartan,
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Figure 3 | Effect of Ang(1–7) and valsartan treatment on the expression of collagen and cytokines in eight groups of rats.
(a) Representative immunostaining of collagen IV, tumor growth factor-b1 (TGF-b1), vascular endothelial growth factor (VEGF), proliferating
cell nuclear antigen (PCNA), and macrophages. (b) Quantitative analysis of collagen IV expression. (c) Quantitative analysis of TGF-b1
expression. (d) Quantitative analysis of VEGF expression. (e) Quantitative analysis of PCNA staining. Bar¼ 50 mm. *Po0.05 vs. the control group;
#Po0.05 vs. the no-treatment group; yPo0.05 vs. the valsartan group. NT: no treatment; S-Ang(1–7): small-dose Ang(1–7); M-Ang(1–7):
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and large-dose Ang(1–7)þ valsartan markedly decreased the
number of proliferating cells. Large-dose Ang(1–7) or large-
dose Ang(1–7)þ valsartan was more effective than valsartan
treatment alone, whereas A779 treatment reversed the
inhibitive effect of Ang(1–7) on the proliferation of HBZY-
1 cells (Figure 4a and d).
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staining. (c) Quantitative analysis of DCF staining. (d) Quantitative analysis of EdU staining. *Po0.05 vs. the control group; #Po0.05 vs. the high-
glucose group; yPo0.05 vs. the valsartan group. HG: high glucose (25mmol/l); S-Ang(1–7): small-dose Ang(1–7) (50 nmol/l); M-Ang(1–7):
moderate-dose Ang(1–7) (100 nmol/l); L-Ang(1–7): large-dose Ang(1–7) (200 nmol/l); valsartan: 10 6 mol/l valsartan; LþV, large-dose
Ang(1–7)þ valsartan; LþA779, large-dose Ang(1–7)þA779 (200 nmol/l).
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Figure 5 | Effect of Ang(1–7) and valsartan treatment on the expression of nicotinamide adenine dinucleotide phosphate oxidase
(NOX) subunits and protein kinase C (PKC) isoforms in eight groups of rats. (a) Western blot analysis of protein expression of NOX4 and
p47phox. (b) Western blot analysis of protein expression of PKCa and PKCb1. (c) Quantitative analysis of a. (d) Quantitative analysis of b.
*Po0.05 vs. the control group; #Po0.05 vs. the no-treatment group; yPo0.05 vs. the valsartan group. NT: no treatment; S-Ang(1–7): small-dose
Ang(1–7); M-Ang(1–7): moderate-dose Ang(1–7); L-Ang(1–7): large-dose Ang(1–7); LþV: large-dose Ang(1–7)þ valsartan; LþA779: large-dose
Ang(1–7)þ A779.
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DISCUSSION
In this study, we demonstrated for the first time that in a rat
model of DN, Ang(1–7) dose-dependently attenuated the
progression of DN, as exhibited by increased creatinine
clearance and reduced ratio of kidney weight to body weight,
24-h urinary volume, 24-h urinary albumin excretion,
plasma creatinine level, and GSI. In addition, we found that
large-dose Ang(1–7) (800 ng/kgmin) treatment was more
effective in ameliorating renal morphology and function than
valsartan treatment, and combined treatment with Ang(1–7)
and valsartan provided no more benefits than large-dose
Ang(1–7) treatment alone. The mechanism of the Ang(1–7)-
mediated effect likely involved attenuated NOX and PKC
expression and inhibited TGF-b1/Smad3 and VEGF signal-
ing. Importantly, the beneficial effect of Ang (1–7) treatment
was essentially offset by combined A779 treatment, suggest-
ing that the effect of Ang(1–7) treatment was mediated
mostly by Mas receptor in the kidney.
In this study, a rat model of diabetes was induced by an
intraperitoneal injection of STZ that has been widely used to
create diabetes models in rodents with pathological features
similar to human diabetes.18 Our results showed that diabetic
rats presented with severe hyperglycemia and renal dysfunc-
tion manifested as increased plasma creatinine level and 24-h
urinary albumin excretion and decreased creatinine clearance,
indicating that a DN animal model was successfully establi-
shed. Interestingly, the kidney weight was similar in diabetic
rats without treatment and in normal rats, and the reason
may be that at the end of the experiment the mean body
weight of the normal rats was more than twofold of that of
the diabetic rats without treatment, and thus the kidney
weight of normal rats increased accordingly, leading to a
similar kidney weight in the two groups. However, the ratio
of kidney weight/body weight in diabetic rats without
treatment was significantly increased compared with that in
normal rats, substantiating the presence of renal hypertrophy
in diabetic rats. Previous studies have shown that
renin–angiotensin system has a key role in the development
of DN,19 and ACE2 overexpression may ameliorate glome-
rular injury and reduce the progression of DN.8 These studies
suggested that the effect of ACE2 on DN may be partly due to
increased Ang(1–7) levels, but the direct evidence was lacking to
support this notion. Although one study showed the potential
of Ang(1–7) to attenuate STZ-induced nephropathy in rats,12
another study reported opposite results.13 Thus, the exact
effect of Ang(1–7) on DN remains unclear. Using the current
animal model, we found that before treatment the serum and
urine levels of Ang(1–7) were lower in all seven groups of
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Figure 6 | Effect of Ang(1–7) and valsartan treatment on the expression of nicotinamide adenine dinucleotide phosphate oxidase
(NOX) subunits and the membrane translocation of protein kinase C (PKC) isoforms in HBZY-1 cells. (a) Western blot analysis of the
protein expression of NOX4 and p47phox. (b) Quantitative analysis of a. (c) Western blot analysis of the protein expression of PKCa and PKCb1 in
the membrane fraction. (d) Western blot analysis of the protein expression of PKCa and PKCb1 in the cytosolic fraction. (e) Quantitative analysis
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diabetic rats than those in the control group of rats, whereas
Ang(1–7) treatment dose-dependently increased the serum
and urinary levels of Ang(1–7) in these treatment groups of
diabetic rats, demonstrating the efficacy of our drug-delivery
approach. It is noteworthy that SBP measured at the end of
the experiment was significantly lower in all seven groups of
diabetic rats than in the control group of rats, which was
consistent with our previous study showing that 16 weeks
after diabetes was induced in rats the cardiac function was
impaired leading to reduced left ventricular ejection fraction
and lowered SBP.20 However, there was no significant
difference in SBP among seven groups of diabetic rats. A
possible explanation was that the impaired cardiac function
may lead to a low SBP in diabetic rats, which may blunt the
antihypertensive effect of valsartan in these animals. In
addition, previous studies found that in animal models of
DN, Ang(1–7) and its antagonist A779 exerted no significant
effect on blood pressure,21,22 which was consistent with our
findings. These results suggested that the renoprotective
effects of Ang(1–7) and valsartan were probably beyond their
effects on SBP.23 Furthermore, we found that Ang(1–7)
and valsartan treatment had no effect on increased blood
glucose levels in diabetic rats, which suggested that the
renoprotective effects of Ang(1–7) and valsartan were
probably independent of glycemic control and lent support
to previous studies.13,24
Glomerular hypertrophy and mesangial matrix expansion
are typical pathological features of DN. We found signifi-
cantly increased extracellular matrix in the glomeruli of the
diabetic rats without treatment as compared with rats of the
control group. Consequently, GSI as a measure of glomerular
sclerosis and the levels of collagen IV and the number
of proliferating cell nuclear antigen-positive cells in the
glomeruli were substantially increased in diabetic rats.
On the other hand, the enhanced extracellular matrix
deposition in glomeruli was dose-dependently attenuated
after Ang(1–7) treatment, suggesting that a large dose of
Ang(1–7) (800 ng/kgmin) is preferable in the treatment of
DN. This finding raised questions about previous studies that
used much less doses of Ang(1–7) in the treatment of
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Figure 7 | Effect of Ang(1–7) and valsartan treatment on the expression of collagen and cytokines in rats and HBZY-1 cells. (a) Western
blot analysis of the protein expression of tumor growth factor-b1 (TGF-b1) and p-Smad3 in glomeruli. (b) Western blot analysis of the protein
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no-treatment group in vivo or the high-glucose group in vitro; yPo0.05 vs. the valsartan group in vivo or in vitro. Col IV, collagen IV; NT, no
treatment; HG, high glucose (25mmol/l); S-Ang(1–7), small-dose Ang(1–7); M-Ang(1–7), moderate-dose Ang(1–7); L-Ang(1–7), large-dose
Ang(1–7); LþV, large-dose Ang(1–7)þ valsartan; LþA779, large-dose Ang(1–7)þA779.
366 Kidney International (2015) 87, 359–369
bas i c resea rch K Zhang et al.: Angiotensin(1–7) attenuates diabetic renal injury
DN.12,13 It has been shown that renal NOX activity and PKC
activation were classic pathways mediating extracellular
matrix expansion in DN.14 A previous study reported that
ACE2 decreased NOX activity and PKC expression possibly
by increasing renal Ang-(1–7) level.7 In addition, Ang(1–7)
could attenuate Ang II–mediated NOX activation in vivo and
in vitro.11,21 In our study, the levels of NOX4, p47phox, PKCa,
and PKCb1 were significantly increased in the glomeruli of
diabetic rats without treatment relative to the control group
of rats. Accordingly, the content of MDA, a product of ROS,
was significantly increased, whereas total SOD activity was
substantially decreased in the kidney of diabetic rats without
treatment. All these changes were attenuated after Ang(1–7)
treatment. A previous study reported a downregulation of the
renal SOD activity by NOXs,25 which may explain why the
renal SOD activity was declined in the no-treatment group
and why it was largely normalized in the large-dose Ang 1–7
group. In the in vitro experiment, the level of ROS and
proliferation of HBZY-1 cells were significantly increased
after high-concentration glucose stimulation, but they were
markedly decreased after Ang(1–7) treatment. The expression
levels of NOX subunits in vitro showed similar changes after
Ang(1–7) treatment. In addition, we examined the membrane
translocation of PKCa and PKCb1 as a marker of their activa-
tion.15 We found that high-concentration glucose stimulation
significantly increased the translocation of PKCa and PKCb1,
and Ang(1–7) dose-dependently suppressed this effect. Thus,
a major mechanism underlying Ang(1–7)-induced thera-
peutic effect on DN may involve suppressed oxidative stress
regulated by NOX and PKC signaling.
Increasing evidence indicates that TGF-b1 promotes the
progression of renal fibrosis and acts as a major mediator of
the hypertrophic and prosclerotic changes in DN.26 Smad3 is
a critical downstream mediator of TGF-b1 in the process of
renal fibrosis,27 and VEGF participates in the development
of podocytopathy and albuminuria in DN.28 The effect of
Ang-(1–7) on TGF-b1/Smad3 and VEGF signaling in kidney
remains in dispute.10,13 In the current study, we examined the
changes of TGF-b1/Smad3 and VEGF expression in DN rats
and HBZY-1 cells. In both in vivo and in vitro experiments,
the expression levels of TGF-b1, VEGF, and the phos-
phorylation levels of Smad3 were increased in DN rats and
high-glucose-stimulated cells, which were suppressed by
Ang(1–7) treatment. These results were in accordance with
previous reports of the effects of Ang(1–7) on the same
signaling pathways in other disease statuses.29,30 Thus,
suppressed TGF-b1/Smad3 and VEGF signal pathway may
underscore another mechanism of Ang(1–7)-mediated effects
on renal fibrosis and albuminura in DN.
To clarify the working receptor through which Ang(1–7)
takes effect, we used combined treatment with Ang(1–7) and
A779, a specific antagonist of Mas receptor, and found that
A779 almost completely blocked the effect of Ang(1–7) both
in vivo and in vitro, suggesting that the therapeutic effect of
Ang(1–7) was via its Mas receptor. This finding was in
accordance with a previous study that used Mas-knockout
mice to study the effect of the Mas receptor on renal
morphology and function.31
An important finding of this study was that after treatment
for 4 weeks, Ang(1–7) dose-dependently ameliorated the renal
morphology and function in diabetic rats, and the therapeutic
effect of large-dose (800 ng/kgmin) Ang(1–7) was superior
to that of valsartan treatment. In line with these therapeu-
tic effects, Ang(1–7) treatment attenuated NOX and PKC
expression and inhibited TGF-b1/Smad3 and VEGF signaling
more effectively than valsartan treatment. In addition, no
detrimental effects of Ang(1–7) treatment on the major organs
of our diabetic rats were observed. However, the combination
of large-dose Ang(1–7) and valsartan treatment did not
provide additional benefit. These results suggest that large-
dose Ang(1–7) may offer a more potent therapeutic armament
than angiotensin receptor blocker, whereas combined treat-
ment of Ang(1–7) and an angiotensin receptor blocker pro-
vides no additive or synergistic effects.
In conclusion, Ang(1–7) dose-dependently ameliorated
STZ-induced diabetic renal injury, and the renoprotective
effect of large-dose Ang(1–7) treatment was superior to
valsartan treatment. The combined treatment of Ang(1–7)
and valsartan had no additive or synergistic effects. The
possible mechanisms of Ang(1–7)-mediated effects involved
reduced renal oxidative stress regulated by NOXs and PKCs,
and inhibited TGF-b1/Smad3 and VEGF signaling.
MATERIALS AND METHODS
Experimental animals and protocol
Male Wistar rats (10 weeks old, 200–250 g) were purchased from the
Animal Center of the Shandong University School of Medicine and
had free access to standard rat chow and water throughout the study.
All procedures were in accordance with the Guide for Care and Use
of Laboratory Animals of Shandong University (Jinan, China). After
acclimatization to the environment for 5 days, 120 rats were
randomly divided into two groups: a control group (n¼ 15) that
received an intraperitoneal injection of normal saline, and a diabetic
group (n¼ 105) that received intraperitoneal injection of 65mg/kg
STZ dissolved in sodium citrate buffer (pH 4.5). The status of
diabetes in rats was confirmed by a tail-blood glucose level higher
than 16.7mmol/l 48 h after STZ injection.32 All diabetic rats received
an intraperitoneal injection of insulin (2–3U) every 3 days to
maintain blood glucose levels between 16.7 and 25mmol/l in order to
prevent rat death induced by excessively high blood glucose levels.
Twelve weeks after STZ injection, diabetic rats were further randomly
divided into seven treatment groups (n¼ 15 per group): no-treatment
group; large-dose, moderate-dose, and small-dose Ang(1–7) groups
that received a subcutaneous injection of 800, 400, and 200 ng/kgmin
of Ang(1–7), respectively, by an embedded mini-osmotic pump;
valsartan group that received an intragastric valsartan at a dose of
30mg/kg per day; large-dose Ang(1–7)þ valsartan (30mg/kg per day)
group; and large-dose Ang(1–7)þA779 (800 ng/kgmin) group. After
treatment for 4 weeks, all rats were killed.
Serum and urinary levels of Ang(1–7)
The levels of Ang-(1–7) in serum and urine were assayed by enzyme-
linked immunosorbent assay (see Supplementary Materials online
for details).
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Biochemical and blood pressure measurements
Blood glucose, SBP, kidney and body weight, 24-h urine volume,
creatinine, and creatinine clearance, as well as 24-h urinary albumin,
were determined in all rats (see Supplementary Materials online for
details).
Renal MDA content and SOD activity levels
The level of MDA and the activity of SOD in glomeruli were
measured in all rat groups (see Supplementary Materials online for
details).
Tissue preparation and histology
Periodic acid–Schiff staining was performed and GSI was calculated
in all rats (see Supplementary Materials online for details).
Immunohistochemistry
Immumohistochemical staining was performed to detect the expres-
sion of collagen IV, TGFb1, VEGF, proliferating cell nuclear antigen,
and macrophages in glomeruli (see Supplementary Materials online
for details).
Cell culture and treatment
Rat glomerular mesangial HBZY-1 cells were purchased from
the China Center for Type Culture Collection and cultured in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum, 100U/ml penicillin, and 100 mg/ml streptomycin at
37 1C in 95% air and 5% CO2. Cells plated on 60-mm dishes were
cultured to 90% confluence and divided into eight groups: control
group, in which cells were incubated in 5mmol/l D-glucose DMEM,
and 20mmol/l D-mannitol was added to the medium in order to
take into the account of the effect of high osmolarity in other cell
groups; no-treatment group, in which cells were stimulated with a
high concentration of glucose (25mmol/l) only for 24 h; small-,
moderate-, and large-dose Ang(1–7) groups, in which cells were pre-
treated with 50, 100, and 200 nmol/l Ang(1–7) for 1 h, respectively;
valsartan group, in which cells were pretreated with 10 6mol/l
valsartan for 1 h; large-dose Ang(1–7)þ valsartan group, in which
cells were pretreated with 200nmol/l Ang(1–7)þ 10 6mol/l valsartan
for 1 h; and large-dose Ang(1–7)þ A779 group, in which cells were
pretreated with 200 nmol/l A779 for 30min and then with 200 nmol/
l Ang(1–7) for 1 h. All cells in the six treatment groups received
stimulation with a high concentration of glucose (25mmol/l)
for 24 h after treatment. Finally, cell protein was extracted for
western blot analysis, and primary antibodies used were the same as
those in experiments in vivo except for mouse monoclonal anti-
VEGF and rabbit polyclonal anti-collagen IV (both 1:1000, Abcam,
Cambridge, UK).
Dihydroethidium and dichlorofluorescein staining and the
5-ethynyl-20-deoxyuridine proliferation assay
Dihydroethidium staining, dichlorofluorescein staining, and the
5-ethynyl-20-deoxyuridine proliferation assay were performed in all
rats (see Supplementary Materials online for details).
Membrane and cytosolic extraction in HBZY-1 cells
Membrane and cytosolic fractions were extracted from cells using
the membrane protein extraction kit (Thermoscientific, Rockford,
IL, USA) (see Supplementary Materials online for details).
Western blot analysis
Western blot analysis was performed to detect the expression levels
of NOX2, p47phox, PKCa, PKCb1, Naþ -Kþ -ATPase, TGF-b1, p-Smad3,
t-Smad3, VEGF, and collagen IV (see Supplementary Materials
online for details).
Statistical analysis
Statistical analysis involved SPSS for Windows v13.0 (SPSS, Chicago,
IL, USA). Data are expressed as mean±s.d. Differences were com-
pared by one-way analysis of variance Po0.05 was considered
statistically significant.
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